The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | ATIR101 after haplo HSCT proves promising
Denis-Claude Roy, MD, University of Montreal, Montreal, QC, Canada, discusses the addition of ATIR101 as an adjunctive treatment given after T-cell-depleted haploidentical HSCT. Data has shown that this may decrease non-relapse mortality and improve survival in hematologic malignancies, irrespective of prognostic risk factors. A global randomized Phase 3 study is currently enrolling to further examine T-cell-depleted haplo HSCT plus ATIR101 compared with T-cell-replete haplo HSCT with post-transplant cyclophosphamide (HATCY; NCT02999854).This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
